Last reviewed · How we verify
Congenital hemolytic uremic syndrome
Approved treatments
- H5G1.1 · AstraZeneca
Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation. - Soliris · Apellis Pharmaceuticals, Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Congenital hemolytic uremic syndrome patent landscape — cliff calendar, originator estates, attackable patents
- Congenital hemolytic uremic syndrome treatment landscape brief
- Congenital hemolytic uremic syndrome treatment updates RSS
Frequently asked questions about Congenital hemolytic uremic syndrome
What drugs treat Congenital hemolytic uremic syndrome?
Tracked treatments include H5G1.1, Soliris.
What is the treatment for Congenital hemolytic uremic syndrome?
Standard treatment for Congenital hemolytic uremic syndrome includes H5G1.1, Soliris. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Congenital hemolytic uremic syndrome patent cliff · Congenital hemolytic uremic syndrome CI report
- Treatment: H5G1.1 · AstraZeneca
- Treatment: Soliris · Apellis Pharmaceuticals, Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing